{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:05:12Z","timestamp":1787317512053,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,1,14]],"date-time":"2009-01-14T00:00:00Z","timestamp":1231891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1007\/s00702-008-0179-4","type":"journal-article","created":{"date-parts":[[2009,1,13]],"date-time":"2009-01-13T10:22:40Z","timestamp":1231842160000},"page":"179-191","source":"Crossref","is-referenced-by-count":39,"title":["Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson\u2019s disease: a systematic review"],"prefix":"10.1007","volume":"116","author":[{"given":"Malcolm","family":"Steiger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Grandas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Van Camp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,1,14]]},"reference":[{"key":"179_CR1","doi-asserted-by":"crossref","unstructured":"Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad, JP, Bertoni et al (1997) Ropinirole for the treatment of early Parkinson\u2019s disease. The Ropinirole Study Group. Neurology 49:393\u2013399","DOI":"10.1212\/WNL.49.2.393"},{"key":"179_CR2","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S1474-4422(07)70218-1","volume":"6","author":"A Antonini","year":"2007","unstructured":"Antonini A, Poewe W (2007) Fibrotic heart-valve reactions to dopamine agonist treatment in Parkinson\u2019s disease. Lancet Neurol 6:826\u2013829","journal-title":"Lancet Neurol"},{"key":"179_CR3","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/0002-8703(74)90251-8","volume":"88","author":"DS Bana","year":"1974","unstructured":"Bana DS, MacNeal PS, LeCompte PM, Shah Y, Graham JR (1974) Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J 88:640\u2013655","journal-title":"Am Heart J"},{"key":"179_CR4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1212\/01.WNL.0000129842.49926.07","volume":"63","author":"DG Baseman","year":"2004","unstructured":"Baseman DG, O\u2019Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB Jr (2004) Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 63:301\u2013304","journal-title":"Neurology"},{"key":"179_CR5","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s007020200040","volume":"109","author":"ER Brunt","year":"2002","unstructured":"Brunt ER, Brooks DJ, Korczyn AD, Montastruc JL, Stocchi F (2002) A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson\u2019s disease not optimally controlled by l-dopa. J Neural Transm 109:489\u2013502","journal-title":"J Neural Transm"},{"key":"179_CR6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0035-3787(04)70850-4","volume":"160","author":"V Calomne","year":"2004","unstructured":"Calomne V, Dupuis MJ, Muller T, Kempinere F (2004) Reversible cardiac valve abnormalities with pergolide treatment. Rev Neurol (Paris) 160:81\u201382","journal-title":"Rev Neurol (Paris)"},{"key":"179_CR7","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(02)11668-0","volume":"360","author":"CE Clarke","year":"2002","unstructured":"Clarke CE, Guttman M (2002) Dopamine agonist monotherapy in Parkinson\u2019s disease. Lancet 360:1767\u20131769","journal-title":"Lancet"},{"key":"179_CR8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","volume":"337","author":"HM Connolly","year":"1997","unstructured":"Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD et al (1997) Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337:581\u2013588","journal-title":"N Engl J Med"},{"key":"179_CR9","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/archneur.64.12.1721","volume":"64","author":"J-C Corvol","year":"2007","unstructured":"Corvol J-C, Anzouan-Kacou J-B, Fauveau E, Bonnet A-M, Lebrun-Vignes B, Girault C et al (2007) Heart valve regurgitation, pergolide use, and Parkinson disease. Arch Neurol 64:1721\u20131726","journal-title":"Arch Neurol"},{"key":"179_CR10","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJM196702162760703","volume":"276","author":"GC Cotzias","year":"1967","unstructured":"Cotzias GC, Van Woert MH, Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med 276:374\u2013379","journal-title":"N Engl J Med"},{"key":"179_CR11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1136\/bmj.316.7126.221","volume":"316","author":"G Davey Smith","year":"1998","unstructured":"Davey Smith G, Egger M (1998) Meta-analysis. Unresolved issues and future developments. BMJ 316:221\u2013225","journal-title":"BMJ"},{"key":"179_CR12","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1001\/archneur.64.3.377","volume":"64","author":"RB Dewey II","year":"2007","unstructured":"Dewey RBII, Reimold SC, O\u2019Suilleabhain PE (2007) Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease. Arch Neurol 64:377\u2013380","journal-title":"Arch Neurol"},{"key":"179_CR13","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00702-005-0289-1","volume":"112","author":"V Dhawan","year":"2005","unstructured":"Dhawan V, Medcalf P, Stegie F, Jackson G, Basu S, Luce P et al (2005) Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson\u2019s disease patients treated with cabergoline. J Neural Transm 112:661\u2013668","journal-title":"J Neural Transm"},{"key":"179_CR14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/bmj.316.7124.61","volume":"316","author":"M Egger","year":"1998","unstructured":"Egger M, Smith GD (1998) Bias in location and selection of studies. BMJ 316:61\u201366","journal-title":"BMJ"},{"key":"179_CR15","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4065\/78.6.730","volume":"78","author":"CM Flowers","year":"2003","unstructured":"Flowers CM, Racoosin JA, Lu SL, Beitz JG (2003) The US Food and Drug Administration\u2019s registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 78:730\u2013731","journal-title":"Mayo Clin Proc"},{"key":"179_CR16","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/mds.20210","volume":"19","author":"K Grosset","year":"2004","unstructured":"Grosset K, Needleman F, Macphee G, Grosset D (2004) Switching from ergot to nonergot dopamine agonists in Parkinson\u2019s disease: a clinical series and five-drug dose conversion table. Mov Disord 19:1370\u20131374","journal-title":"Mov Disord"},{"key":"179_CR17","first-page":"235","volume":"5","author":"M Hendrikx","year":"1996","unstructured":"Hendrikx M, Van Dorpe J, Flameng W, Daenen W (1996) Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. J Heart Valve Dis 5:235\u2013237","journal-title":"J Heart Valve Dis"},{"key":"179_CR18","first-page":"1044","volume":"61","author":"RG Holloway","year":"2004","unstructured":"Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K et al (2004) Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61:1044\u20131053","journal-title":"Arch Neurol"},{"key":"179_CR19","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/mds.20201","volume":"19","author":"J Horvath","year":"2004","unstructured":"Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S et al (2004) Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 19:656\u2013662","journal-title":"Mov Disord"},{"key":"179_CR20","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/01.CIR.101.17.2071","volume":"101","author":"JG Jollis","year":"2000","unstructured":"Jollis JG, Landolfo CK, Kisslo J, Constantine GD, Davis KD, Ryan T (2000) Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 101:2071\u20132077","journal-title":"Circulation"},{"key":"179_CR21","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/mds.21225","volume":"22","author":"S Junghanns","year":"2007","unstructured":"Junghanns S, Fuhrmann JT, Simonis G, Oelwein C, Koch R, Strasser RH et al (2007) Valvular heart disease in Parkinson\u2019s disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Mov Disord 22:234\u2013238","journal-title":"Mov Disord"},{"key":"179_CR22","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clineuro.2007.01.011","volume":"109","author":"G Kenangil","year":"2007","unstructured":"Kenangil G, Ozekmekci S, Koldas L, Sahin T, Erginoz E (2007) Assessment of valvulopathy in Parkinson\u2019s disease patients on pergolide and\/or cabergoline. Clin Neurol Neurosurg 109:350\u2013353","journal-title":"Clin Neurol Neurosurg"},{"key":"179_CR23","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/mds.20931","volume":"21","author":"JY Kim","year":"2006","unstructured":"Kim JY, Chung EJ, Park SW, Lee WY (2006) Valvular heart disease in Parkinson\u2019s disease treated with ergot derivative dopamine agonists. Mov Disord 21:1261\u20131264","journal-title":"Mov Disord"},{"key":"179_CR24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1212\/WNL.49.1.162","volume":"49","author":"A Lieberman","year":"1997","unstructured":"Lieberman A, Ranhosky A, Korts D (1997) Clinical evaluation of pramipexole in advanced Parkinson\u2019s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 49:162\u2013168","journal-title":"Neurology"},{"key":"179_CR25","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1212\/WNL.51.4.1057","volume":"51","author":"A Lieberman","year":"1998","unstructured":"Lieberman A, Olanow CW, Sethi K, Swanson P, Waters CH, Fahn S et al (1998) A multicenter trial of ropinirole as adjunct treatment for Parkinson\u2019s disease. Ropinirole Study Group. Neurology 51:1057\u20131062","journal-title":"Neurology"},{"key":"179_CR26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(77)91146-1","volume":"1","author":"CD Marsden","year":"1977","unstructured":"Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson\u2019s disease. Lancet 1:345\u2013349","journal-title":"Lancet"},{"key":"179_CR27","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/jpet.102.039867","volume":"303","author":"MJ Millan","year":"2002","unstructured":"Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303:791\u2013804","journal-title":"J Pharmacol Exp Ther"},{"key":"179_CR28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1212\/WNL.58.1.11","volume":"58","author":"JM Miyasaki","year":"2002","unstructured":"Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE (2002) Practice parameter: initiation of treatment for Parkinson\u2019s disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 58:11\u201317","journal-title":"Neurology"},{"key":"179_CR29","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/mds.10508","volume":"18","author":"Y Mizuno","year":"2003","unstructured":"Mizuno Y, Yanagisawa N, Kuno S, Yamamoto M, Hasegawa K, Origasa H et al (2003) Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson\u2019s disease. Mov Disord 18:1149\u20131156","journal-title":"Mov Disord"},{"key":"179_CR30","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/jpet.102.039883","volume":"303","author":"A Newman-Tancredi","year":"2002","unstructured":"Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verriele L, Carpentier N et al (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 303:815\u2013822","journal-title":"J Pharmacol Exp Ther"},{"key":"179_CR31","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1212\/WNL.40.2.340","volume":"40","author":"JG Nutt","year":"1990","unstructured":"Nutt JG (1990) Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 40:340\u2013345","journal-title":"Neurology"},{"key":"179_CR32","first-page":"11","volume":"39","author":"JA Obeso","year":"1989","unstructured":"Obeso JA, Grandas F, Vaamonde J, Luquin MR, Artieda J, Lera G et al (1989) Motor complications associated with chronic levodopa therapy in Parkinson\u2019s disease. Neurology 39:11\u201319","journal-title":"Neurology"},{"key":"179_CR33","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1212\/01.wnl.0000215250.82576.87","volume":"66","author":"R Pahwa","year":"2006","unstructured":"Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H et al (2006) Practice parameter: treatment of Parkinson\u2019s disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:983\u2013995","journal-title":"Neurology"},{"key":"179_CR34","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/mds.20887","volume":"21","author":"C Peralta","year":"2006","unstructured":"Peralta C, Wolf E, Alber H, Seppi K, Muller S, Bosch S et al (2006) Valvular heart disease in Parkinson\u2019s disease vs. controls: an echocardiographic study. Mov Disord 21:1109\u20131113","journal-title":"Mov Disord"},{"key":"179_CR35","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJM200511033531822","volume":"353","author":"A Pinero","year":"2005","unstructured":"Pinero A, Marcos-Alberca P, Fortes J (2005) Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 353:1976\u20131977","journal-title":"N Engl J Med"},{"key":"179_CR36","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.4065\/77.12.1280","volume":"77","author":"AM Pritchett","year":"2002","unstructured":"Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE (2002) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77:1280\u20131286","journal-title":"Mayo Clin Proc"},{"key":"179_CR37","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342:1484\u20131491","journal-title":"N Engl J Med"},{"key":"179_CR38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.7326\/0003-4819-117-1-50","volume":"117","author":"MM Redfield","year":"1992","unstructured":"Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ (1992) Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 117:50\u201352","journal-title":"Ann Intern Med"},{"key":"179_CR39","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s00415-007-0592-x","volume":"254","author":"E Ruzicka","year":"2007","unstructured":"Ruzicka E, Linkova H, Penicka M, Ulmanova O, Novakova L, Roth J (2007) Low incidence of restrictive valvulopathy in patients with Parkinson\u2019s disease on moderate dose of pergolide. J Neurol 254:1575\u20131578","journal-title":"J Neurol"},{"key":"179_CR40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","volume":"356","author":"R Schade","year":"2007","unstructured":"Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29\u201338","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"179_CR41","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/00019052-200312001-00006","volume":"16","author":"J Schwarz","year":"2003","unstructured":"Schwarz J (2003) Rationale for dopamine agonist use as monotherapy in Parkinson\u2019s disease. Curr Opin Neurol 16(Suppl 1):S27\u2013S33","journal-title":"Curr Opin Neurol"},{"key":"179_CR42","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00045415-200211000-00005","volume":"10","author":"J Serratrice","year":"2002","unstructured":"Serratrice J, Disdier P, Habib G, Viallet F, Weiller PJ (2002) Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 10:334\u2013336","journal-title":"Cardiol Rev"},{"key":"179_CR43","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1161\/01.CIR.100.21.2161","volume":"100","author":"BK Shively","year":"1999","unstructured":"Shively BK, Roldan CA, Gill EA, Najarian T, Loar SB (1999) Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation 100:2161\u20132167","journal-title":"Circulation"},{"key":"179_CR44","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0002-9149(98)01064-9","volume":"83","author":"JP Singh","year":"1999","unstructured":"Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL et al (1999) Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 83:897\u2013902","journal-title":"Am J Cardiol"},{"key":"179_CR45","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008\u20132012","journal-title":"JAMA"},{"key":"179_CR46","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1212\/01.WNL.0000083985.00343.F2","volume":"61","author":"G Camp Van","year":"2003","unstructured":"Van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D (2003) Heart valvular disease in patients with Parkinson\u2019s disease treated with high-dose pergolide. Neurology 61:859\u2013861","journal-title":"Neurology"},{"key":"179_CR47","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(04)15945-X","volume":"363","author":"G Camp Van","year":"2004","unstructured":"Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M et al (2004) Treatment of Parkinson\u2019s disease with pergolide and relation to restrictive valvular heart disease. Lancet 363:1179\u20131183","journal-title":"Lancet"},{"key":"179_CR48","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.4065\/80.8.1016","volume":"80","author":"EA Waller","year":"2005","unstructured":"Waller EA, Kaplan J, Heckman MG (2005) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 80:1016\u20131020","journal-title":"Mayo Clin Proc"},{"key":"179_CR49","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/oxfordjournals.eurheartj.a015324","volume":"18","author":"A Wilke","year":"1997","unstructured":"Wilke A, Hesse H, Hufnagel G, Maisch B (1997) Mitral, aortic and tricuspid valvular heart disease associated with ergotamine therapy for migraine. Eur Heart J 18:701","journal-title":"Eur Heart J"},{"key":"179_CR50","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1212\/01.wnl.0000238508.68593.1d","volume":"67","author":"M Yamamoto","year":"2006","unstructured":"Yamamoto M, Uesugi T, Nakayama T (2006) Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 67:1225\u20131229","journal-title":"Neurology"},{"key":"179_CR51","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/mds.22036","volume":"23","author":"K Yamashiro","year":"2008","unstructured":"Yamashiro K, Komine-Kobayashi M, Hatano T, Urabe T, Mochizuki H, Hattori N et al (2008) The frequency of cardiac valvular regurgitation in Parkinson\u2019s disease. Mov Disord 23:935\u2013941","journal-title":"Mov Disord"},{"key":"179_CR52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","volume":"356","author":"R Zanettini","year":"2007","unstructured":"Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease. N Engl J Med 356:39\u201346","journal-title":"N Engl J Med"},{"key":"179_CR53","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0894-7317(03)00335-3","volume":"16","author":"WA Zoghbi","year":"2003","unstructured":"Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA et al (2003) Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16:777\u2013802","journal-title":"J Am Soc Echocardiogr"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-008-0179-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-008-0179-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-008-0179-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:25:12Z","timestamp":1559089512000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-008-0179-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,14]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["179"],"URL":"https:\/\/doi.org\/10.1007\/s00702-008-0179-4","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,14]]}}}